喘息治療薬市場：製品、薬剤クラス別、投与経路別-2023-2030年の世界予測

喘息治療薬市場規模は2022年に223億9,000万米ドルと推計され、2023年には247億米ドルに達し、CAGR 10.59%で2030年には501億米ドルに達すると予測されます。

喘息治療薬の世界市場

喘息治療薬市場には、慢性呼吸器疾患である喘息の症状を管理・緩和するための薬や治療法の研究開発、生産、流通に関連するすべての活動が含まれます。この市場は、喘息エピソードの維持療法または急性期治療を必要とする、年齢層を超えた多様な患者集団を対象としています。市場範囲には、抗炎症薬、気管支拡張薬、併用療法、生物学的製剤、吸入器やネブライザーなどのデリバリー・デバイスなど、さまざまな治療薬が含まれます。喘息治療薬市場における主な用途には、安定した状態を維持することを目的とした長期管理薬や、突発的な症状に対する即効性のある治療薬が含まれます。これらの製品のエンドユーザーは通常、喘息と診断された個人、呼吸器専門医のようなヘルスケア専門家、および病院、クリニック、在宅ケア環境などのヘルスケア環境です。その範囲は、患者教育や喘息管理機器の適切な使用に関するトレーニングなどのサポートサービスにも及ぶ。喘息治療薬のニーズは、喘息やその他の呼吸器疾患の罹患率の増加、アレルギー検出・診断技術の最近の向上、モノクローナル抗体の広範な需要により増加しています。しかし、喘息治療薬市場は、喘息治療器具の限界や副作用、高度な治療に伴う高額な費用、遠隔地や農村部における治療範囲の限定などの課題に直面しています。一方、喘息治療薬市場には、治療のための併用治療薬の市場開拓や、喘息治療のための広範な研究開発（R&D）など、いくつかのビジネスチャンスが生まれつつあります。また、使用状況を追跡して患者に服用を思い出させることができるスマート吸入器など、デジタルヘルスソリューションに向かう傾向も強まっており、ハイテク企業や製薬企業との提携にチャンスが広がっています。

地域別の洞察

米国の喘息治療薬市場は、喘息の高い有病率と強力なヘルスケアインフラによって牽引されています。特許の失効、新規生物製剤、個別化医療がこの地域の研究とイノベーションを促進しています。同地域のさまざまな組織が、喘息、食物アレルギー、鼻アレルギー、その他のアレルギー性疾患の治療法を発見し、コントロールし続けています。南米では喘息治療薬に対するニーズが高まっているが、これは呼吸器疾患に対する意識の高まりとヘルスケア施設の改善によるところが大きいです。欧州は喘息治療薬の実質的な市場であり、高い認知度、確立されたヘルスケアシステム、有利な償還政策に支えられています。複数の主要市場参入企業が存在し、研究開発活動が重視されていることも特筆すべき要因です。ドイツ、フランス、スイス、英国、フランス、イタリアなどの西欧諸国が主要な市場シェアを占める一方、東欧諸国は医療インフラの改善と喘息有病率の上昇により成長の可能性を示しています。中東の市場は、医療インフラの整備と民間セクターの投資増加によって進展しています。一方、アフリカでは、医療サービスの制限、認知度の低さ、治療への不十分なアクセスといった課題に直面しており、これが市場成長の妨げとなっています。しかし、南アフリカをはじめとする特定の諸国は、喘息治療において進歩を遂げており、地域市場開拓にプラスの影響を与える可能性があります。APACでは、中国の喘息治療市場が、中間層の増加とヘルスケア改革の強化により急速に発展しています。日本では、高度なヘルスケア制度と患者の高い意識を反映して、患者は最先端の治療法をいくつか利用できます。日本の製薬部門は非常に革新的で、新薬のパイプラインは充実しており、研究開発への投資も継続的に行われています。インドの喘息治療市場は、手頃な価格の医薬品へのニーズと喘息管理に関する教育の充実を特徴としています。人口が多く、公害問題も相まって、喘息の有病率が高まっています。政府のプログラムや非営利のイニシアチブは、亜大陸全域で喘息治療へのアクセス性と手頃な価格の向上を目指しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは喘息治療薬市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、喘息治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-喘息治療薬市場の市場規模および予測は？

2-喘息治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-喘息治療薬市場における技術動向と規制の枠組みは？

4-喘息治療薬市場における主要ベンダーの市場シェアは？

5-喘息治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 喘息およびその他の呼吸器疾患の発生率の増加
    • アレルギー検出および診断技術の最近の進歩
    • モノクローナル抗体に対する広範な需要
  • 抑制要因
    • 喘息治療器具の限界と副作用
  • 機会
    • 治療のための併用療法の開発
    • 喘息治療のための広範な研究開発（R&D）への取り組み
  • 課題
    • 遠隔地や農村地域では治療薬の範囲が限られている
• 市場セグメンテーション分析
  • 製品：喘息治療用定量吸入器の需要の高まり
  • 薬剤クラス：喘息治療薬で抗炎症薬の使用が増加
  • 投与経路：迅速な症状緩和のために吸入喘息治療薬の採用を拡大
• 市場動向分析
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 喘息治療薬市場：製品別

• 吸入器
  • ドライパウダー吸入器
  • 定量吸入器
  • ソフトミスト吸入器
• ネブライザー

第7章 喘息治療薬市場薬剤クラス別

• 抗炎症
• 気管支拡張薬
• 併用療法

第8章 喘息治療薬市場：投与経路別

• 吸入した
• オーラル

第9章 南北アメリカの喘息治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の喘息治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの喘息治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ主要企業別の分析
  • 合併・買収
  • 契約、コラボレーション、パートナーシップ
  • 新製品発売と機能強化

第13章 競争力のあるポートフォリオ

• 主要な企業プロファイル
  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Chiesi Farmaceutici S.p.A.
  • Cipla Limited
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Kare Medical and Analytical Devices Ltd. Co.
  • Koninklijke Philips N.V.
  • Lupin Limited
  • Medtronic PLC
  • Merck & Co, Inc.
  • Merxin Ltd.
  • Novartis AG
  • Parekhplast India Limited
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Shenzhen Aeon Technology Co., Ltd.
  • Softhale NV by invoX Pharma Limited
  • Sun Pharmaceutical Industries Limited
  • Sunovion Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries Ltd.
  • Trudell Medical Limited
  • Viatris Inc.
  • Wellinks, Inc.
• 主要な製品ポートフォリオ

第14章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. ASTHMA THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. ASTHMA THERAPEUTICS MARKET SIZE, 2022 VS 2030
• FIGURE 3. ASTHMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 5. ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 6. ASTHMA THERAPEUTICS MARKET DYNAMICS
• FIGURE 7. ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
• FIGURE 8. ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
• FIGURE 10. ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
• FIGURE 12. ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
• FIGURE 14. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
• FIGURE 16. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 21. ASTHMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 22. ASTHMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. ASTHMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. ASTHMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 6. ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 8. ASTHMA THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. ASTHMA THERAPEUTICS MARKET SIZE, BY METERED-DOSE INHALERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. ASTHMA THERAPEUTICS MARKET SIZE, BY SOFT MIST INHALERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 13. ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. ASTHMA THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. ASTHMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 17. ASTHMA THERAPEUTICS MARKET SIZE, BY INHALED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 32. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 33. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 34. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 35. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 50. AUSTRALIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 51. AUSTRALIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 54. CHINA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 55. CHINA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 56. CHINA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 57. CHINA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. INDIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. INDIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 60. INDIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 61. INDIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. INDONESIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. INDONESIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 64. INDONESIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. JAPAN ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. JAPAN ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 68. JAPAN ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. MALAYSIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. MALAYSIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 72. MALAYSIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. PHILIPPINES ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. PHILIPPINES ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 76. PHILIPPINES ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. SINGAPORE ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. SINGAPORE ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 80. SINGAPORE ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. SOUTH KOREA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. SOUTH KOREA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH KOREA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. TAIWAN ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. TAIWAN ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 88. TAIWAN ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. THAILAND ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. THAILAND ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 92. THAILAND ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. VIETNAM ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. VIETNAM ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 96. VIETNAM ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 103. DENMARK ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. DENMARK ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 105. DENMARK ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. EGYPT ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 108. EGYPT ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 109. EGYPT ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. FINLAND ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 112. FINLAND ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 113. FINLAND ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. FRANCE ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. FRANCE ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 117. FRANCE ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. GERMANY ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. GERMANY ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 121. GERMANY ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. ISRAEL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. ISRAEL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 125. ISRAEL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. ITALY ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 128. ITALY ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 129. ITALY ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 130. ITALY ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. NETHERLANDS ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. NETHERLANDS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 133. NETHERLANDS ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. NIGERIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 136. NIGERIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 137. NIGERIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. NORWAY ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. NORWAY ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 141. NORWAY ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. POLAND ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 144. POLAND ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 145. POLAND ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 146. POLAND ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 147. QATAR ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 148. QATAR ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 149. QATAR ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 150. QATAR ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 151. RUSSIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 152. RUSSIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 153. RUSSIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. SAUDI ARABIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 156. SAUDI ARABIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 157. SAUDI ARABIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 159. SOUTH AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 160. SOUTH AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 163. SPAIN ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 164. SPAIN ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 165. SPAIN ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 167. SWEDEN ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 168. SWEDEN ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 169. SWEDEN ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 171. SWITZERLAND ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 172. SWITZERLAND ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 173. SWITZERLAND ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. TURKEY ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 176. TURKEY ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 177. TURKEY ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. UNITED ARAB EMIRATES ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 180. UNITED ARAB EMIRATES ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 181. UNITED ARAB EMIRATES ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 183. UNITED KINGDOM ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 184. UNITED KINGDOM ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 185. UNITED KINGDOM ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 187. ASTHMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 188. ASTHMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 189. ASTHMA THERAPEUTICS MARKET LICENSE & PRICING

[183 Pages Report] The Asthma Therapeutics Market size was estimated at USD 22.39 billion in 2022 and expected to reach USD 24.70 billion in 2023, at a CAGR 10.59% to reach USD 50.10 billion by 2030.

Global Asthma Therapeutics Market

The asthma therapeutics market encompasses all activities related to the research, development, production, and distribution of medications and treatments designed to manage and alleviate the symptoms of asthma, a chronic respiratory disorder. This market serves a diverse population of patients across age groups who require either maintenance therapy or acute care for asthmatic episodes. The market scope includes various therapeutic products such as anti-inflammatory drugs, bronchodilators, combination therapies, biologics, and delivery devices such as inhalers and nebulizers. The primary applications within the asthma therapeutics market include long-term control medicines, which aim to maintain a stable condition, and quick-relief treatments for sudden symptoms. End-users of these products typically entail individuals diagnosed with asthma, healthcare professionals like pulmonologists, and healthcare settings, including hospitals, clinics, and homecare environments. The scope extends to support services like patient education and training on the proper use of asthma management devices. The need for asthma therapeutics is increasing due to growing incidences of asthma and other respiratory diseases, recent improvements in allergy detection and diagnostic technologies, and extensive demand for monoclonal antibodies. However, the asthma therapeutics market faces certain challenges, including limitations and side effects of asthma therapeutic devices, high costs associated with advanced treatments, and limited therapeutic reach in remote and rural areas. On the other hand, several opportunities are emerging within the asthma therapeutics market, including the development of combination therapeutics for the treatment and extensive research and development (R&D) efforts for asthma treatment. There is also an increasing trend towards digital health solutions, such as smart inhalers that can track usage and remind patients about doses, opening opportunities for tech companies and pharmaceutical partnerships.

Regional Insights

In the United States, the asthma therapeutics market is driven by a high prevalence of asthma alongside strong healthcare infrastructure. Patent expirations, novel biologics, and personalized medicine drive research and innovation in the region. Various organizations in the region continue to find a cure for and control asthma, food allergies, nasal allergies, and other allergic diseases. South America shows a growing need for asthma therapeutics, largely due to increasing awareness of respiratory diseases and improving healthcare facilities. Europe represents a substantial market for asthma therapeutics, supported by high awareness levels, established healthcare systems, and favorable reimbursement policies. The presence of several key market players and a strong emphasis on research and development activities are notable factors. Western European countries, including Germany, France, Switzerland, the United Kingdom, France, and Italy, hold a major market share, while Eastern European countries exhibit potential for growth due to improving healthcare infrastructure and rising asthma prevalence. The market in the Middle East is advancing with the development of healthcare infrastructure and increasing private sector investment. In contrast, Africa faces challenges such as limited healthcare services, low awareness, and inadequate access to treatment, which hinder market growth. However, certain countries, including South Africa, are making strides in asthma care, which can positively influence regional market development. In APAC, China's asthma therapeutic market is developing rapidly due to the growing middle class and enhanced healthcare reforms. In Japan, patients have access to several state-of-the-art treatments, reflecting the country's advanced healthcare system and high patient awareness. Japan's pharmaceutical sector is highly innovative, with a robust pipeline of new drugs and consistent investment in R&D. India's asthma treatment market is characterized by a need for affordable medications and increased education on asthma management. The high population, coupled with pollution issues, contributes to a growing prevalence of asthma. Government programs and non-profit initiatives aim to enhance asthma care accessibility and affordability throughout the subcontinent.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Asthma Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Asthma Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Asthma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Biogen Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Chiesi Farmaceutici S.p.A., Cipla Limited, F. Hoffmann-La Roche Ltd, Genentech, Inc., GlaxoSmithKline PLC, Kare Medical and Analytical Devices Ltd. Co., Koninklijke Philips N.V., Lupin Limited, Medtronic PLC, Merck & Co, Inc., Merxin Ltd., Novartis AG, Parekhplast India Limited, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Shenzhen Aeon Technology Co., Ltd., Softhale NV by invoX Pharma Limited, Sun Pharmaceutical Industries Limited, Sunovion Pharmaceuticals, Inc., Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., Trudell Medical Limited, Viatris Inc., and Wellinks, Inc..

Market Segmentation & Coverage

This research report categorizes the Asthma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Inhalers
    • Dry Powder Inhalers
    • Metered-Dose Inhalers
    • Soft Mist Inhalers
  • Nebulizers
• Drug Class
  • Anti-Inflammatory
  • Bronchodilators
  • Combination Therapy
• Route of administration
  • Inhaled
  • Oral
• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Asthma Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Asthma Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Asthma Therapeutics Market?

4. What is the market share of the leading vendors in the Asthma Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Asthma Therapeutics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Asthma Therapeutics Market, by Region

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing Incidences of Asthma and Other Respiratory Diseases
    • 5.1.1.2. Recent Improvements in Allergy Detection and Diagnostic Technologies
    • 5.1.1.3. Extensive Demand for Monoclonal Antibodies
  • 5.1.2. Restraints
    • 5.1.2.1. Limitation and Side Effects of Asthma Therapeutic Devices
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of Combination Therapeutics for The Treatment
    • 5.1.3.2. Extensive Research and Development (R&D) Efforts for Asthma Treatment
  • 5.1.4. Challenges
    • 5.1.4.1. Limited Therapeutics Reach in Remote & Rural Areas
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Rising demand for metered dose inhalers for the treatment of asthma
  • 5.2.2. Drug Class: Growing usage of anti-Inflammatory drugs in asthma therapeutics
  • 5.2.3. Route of administration: Expanding adoption of inhaled asthma medication for fast relief
• 5.3. Market Trend Analysis
• 5.4. Cumulative Impact of COVID-19
• 5.5. Cumulative Impact of Russia-Ukraine Conflict
• 5.6. Cumulative Impact of High Inflation
• 5.7. Porter's Five Forces Analysis
  • 5.7.1. Threat of New Entrants
  • 5.7.2. Threat of Substitutes
  • 5.7.3. Bargaining Power of Customers
  • 5.7.4. Bargaining Power of Suppliers
  • 5.7.5. Industry Rivalry
• 5.8. Value Chain & Critical Path Analysis
• 5.9. Regulatory Framework
• 5.10. Client Customization

6. Asthma Therapeutics Market, by Product

• 6.1. Introduction
• 6.2. Inhalers
  • 6.3.1. Dry Powder Inhalers
  • 6.3.2. Metered-Dose Inhalers
  • 6.3.3. Soft Mist Inhalers
• 6.3. Nebulizers

7. Asthma Therapeutics Market, by Drug Class

• 7.1. Introduction
• 7.2. Anti-Inflammatory
• 7.3. Bronchodilators
• 7.4. Combination Therapy

8. Asthma Therapeutics Market, by Route of administration

• 8.1. Introduction
• 8.2. Inhaled
• 8.3. Oral

9. Americas Asthma Therapeutics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Asthma Therapeutics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Asthma Therapeutics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player
  • 12.3.1. Merger & Acquisition
    • 12.3.1.1. GSK Boosts Respiratory Portfolio with $1.4 Billion Aiolos Bio Acquisition
  • 12.3.2. Agreement, Collaboration, & Partnership
    • 12.3.2.1. Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
  • 12.3.3. New Product Launch & Enhancement
    • 12.3.3.1. Lupin Launches Luforbec® 100/6 for Adult Asthma and COPD Treatment

13. Competitive Portfolio

• 13.1. Key Company Profiles
  • 13.1.1. Abbott Laboratories
  • 13.1.2. Amgen Inc.
  • 13.1.3. AstraZeneca PLC
  • 13.1.4. Biogen Inc.
  • 13.1.5. Boehringer Ingelheim GmbH
  • 13.1.6. Boston Scientific Corporation
  • 13.1.7. Chiesi Farmaceutici S.p.A.
  • 13.1.8. Cipla Limited
  • 13.1.9. F. Hoffmann-La Roche Ltd
  • 13.1.10. Genentech, Inc.
  • 13.1.11. GlaxoSmithKline PLC
  • 13.1.12. Kare Medical and Analytical Devices Ltd. Co.
  • 13.1.13. Koninklijke Philips N.V.
  • 13.1.14. Lupin Limited
  • 13.1.15. Medtronic PLC
  • 13.1.16. Merck & Co, Inc.
  • 13.1.17. Merxin Ltd.
  • 13.1.18. Novartis AG
  • 13.1.19. Parekhplast India Limited
  • 13.1.20. Pfizer Inc.
  • 13.1.21. Regeneron Pharmaceuticals, Inc.
  • 13.1.22. Sanofi S.A.
  • 13.1.23. Shenzhen Aeon Technology Co., Ltd.
  • 13.1.24. Softhale NV by invoX Pharma Limited
  • 13.1.25. Sun Pharmaceutical Industries Limited
  • 13.1.26. Sunovion Pharmaceuticals, Inc.
  • 13.1.27. Takeda Pharmaceutical Company
  • 13.1.28. Teva Pharmaceutical Industries Ltd.
  • 13.1.29. Trudell Medical Limited
  • 13.1.30. Viatris Inc.
  • 13.1.31. Wellinks, Inc.
• 13.2. Key Product Portfolio

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing